
According to an evaluation of the cost effectiveness of immunoprophylaxis with palivizumab against respiratory syncytial virus infection, based on actual cost and observed RSV incidence rates in various pediatric risk groups during the 2004 to 2005 RSV infection season in Florida, the answer is no.




